Thetis cells, a class of immune cells first described in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of ...

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of food-associated allergic and inflammatory diseases.

A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of ...

today announced a partnership with Quell Therapeutics ("Quell"), a clinical-stage biotechnology company pioneering engineered T-regulatory (Treg) cell therapies. This collaboration supports the ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...

This allowed Thetis cells to program another type of immune cell called regulatory T cells to suppress the immune response to the egg protein, essentially telling the body it was safe. Dr. Vanja ...

SEATTLE & MILAN, May 15, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a partnership with Quell Therapeutics ("Quell"), a clinical-stage biotechnology company ...

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and ...